The prospect of lactoferrin use as adjunctive agent in management of SARS-CoV-2 patients: a randomized pilot study

Fahad Dhafer Algahtani, Mohamed Tharwat Elabbasy, Mai A Samak, Adeniyi A Adeboye, Rafeek A Yusuf, Mohamed E Ghoniem

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
1 Downloads (Pure)

Abstract

Background and Objectives: Preventive, adjunctive and curative properties of lactoferrin have been evaluated since the first wave of severe acute respiratory syndrome coronavirus (SARS-CoV), a viral respiratory disease, emerged 18 years ago. Despite the discovery of new vaccine candidates, there is currently no widely approved treatment for SARS-CoV-2 (COVID-19). Strict adherence to infection prevention and control procedures, as well as vaccines, can, however, prevent the spread of SARS-CoV-2. This study aimed to evaluate the efficacy of lactoferrin treatment in improving clinical symptoms and laboratory indices among individuals with mild to moderate coronavirus disease-19 (COVID-19). Materials and Method: A randomized, prospective, interventional pilot study conducted between 8 July and 18 September 2020 used a hospital-based sample of 54 laboratory-confirmed participants with mild to moderate symptoms of COVID-19. Randomization into a control and two treatment groups ensured all groups received the approved Egyptian COVID-19 management protocol; only treatment group participants received lactoferrin at different doses for seven days. Clinical symptoms and laboratory indices were assessed on Days 0, 2 and 7 after starting treatments. Mean values with standard deviation and one-way analysis of variance with least significant difference of demographic and laboratory data between control and treatment groups were calculated. Results: Our study showed no statistically significant difference among studied groups regarding recovery of symptoms or laboratory improvement. Conclusions: Further research into therapeutic properties particularly related to dosage, duration and follow-up after treatment with lactoferrin in individuals with COVID-19 is required.

Original languageEnglish
JournalMedicina (Kaunas, Lithuania)
Volume57
Issue number8
DOIs
Publication statusPublished - 19 Aug 2021
Externally publishedYes

Keywords

  • COVID-19
  • Humans
  • Lactoferrin/therapeutic use
  • Pilot Projects
  • Prospective Studies
  • SARS-CoV-2
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'The prospect of lactoferrin use as adjunctive agent in management of SARS-CoV-2 patients: a randomized pilot study'. Together they form a unique fingerprint.

Cite this